Zelira Therapeutics (AU:ZLD)
ASX:ZLD
Top Page
Zelira Therapeutics
(Sydney:ZLD)
Select Model
Select Model
Rating:39Underperform
Price Target:
AU$0.47
▲(39.12% Upside)
Action:DowngradedDate:02/25/26
The score is held down primarily by very weak financial performance (sharp revenue decline, ongoing losses, negative equity, and negative cash flows). Technical indicators also lean bearish (below key short-term averages and negative MACD), while valuation signals are constrained by a negative P/E and lack of dividend yield data.
Positive Factors
Focused cannabinoid therapeutics
Zelira’s clear strategic focus on cannabinoid-based medicines and regulated product commercialisation creates a durable niche. End-to-end capabilities across R&D, clinical evaluation and regulated commercialization support sustained product development and differentiated market positioning over months.
Negative Factors
Severe revenue decline
A near-total revenue collapse drastically reduces operating scale and undermines the business model’s ability to fund R&D, regulatory processes and commercialization. Over a multi-month horizon this weakens bargaining power with partners and raises execution risk for clinical programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused cannabinoid therapeutics
Zelira’s clear strategic focus on cannabinoid-based medicines and regulated product commercialisation creates a durable niche. End-to-end capabilities across R&D, clinical evaluation and regulated commercialization support sustained product development and differentiated market positioning over months.
Read all positive factors
Zelira Therapeutics (ZLD) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.95M
Dividend YieldN/A
Average Volume (3M)1.92K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue Growth-99.31%
EPS Growth90.20%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,897,155
10 Day Avg. Volume1,056
30 Day Avg. Volume1,924
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zelira Therapeutics Business Overview & Revenue Model
Company Description
Zelira Therapeutics (ZLD) is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid-based therapeutics. Operating primarily in the healthcare sector, Zelira aims to address various health conditions,...
How the Company Makes Money
Zelira Therapeutics generates revenue primarily through the sale of its proprietary cannabinoid-based products, which are marketed to both consumers and healthcare providers. The company also engages in partnerships and collaborations with other p...
Zelira Therapeutics Financial Statement Overview
Summary
Income Statement
10
Very Negative
Balance Sheet
15
Very Negative
Cash Flow
20
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 656.00 | 94.95K | 301.12K | 1.54M | 663.32K |
| Gross Profit | -802.95K | 10.28K | -3.22M | -5.72M | -39.16K |
| EBITDA | -4.17M | -36.44M | -6.79M | -13.06M | -9.41M |
| Net Income | -3.63M | -36.57M | -5.57M | -11.95M | -8.55M |
Balance Sheet | |||||
| Total Assets | 1.30M | 5.18M | 33.89M | 37.70M | 39.37M |
| Cash, Cash Equivalents and Short-Term Investments | 5.66K | 586.16K | 146.21K | 2.75M | 4.97M |
| Total Debt | 2.14M | 5.95M | 437.90K | 500.91K | 551.08K |
| Total Liabilities | 5.59M | 9.36M | 2.18M | 2.01M | 1.54M |
| Stockholders Equity | -4.46M | -4.51M | 31.80M | 35.20M | 37.83M |
Cash Flow | |||||
| Free Cash Flow | -4.91M | -4.39M | -7.25M | -9.43M | -8.62M |
| Operating Cash Flow | -4.91M | -4.39M | -7.25M | -9.43M | -8.62M |
| Investing Cash Flow | 1.15M | 919.74K | 2.83M | -207.78K | 1.38M |
| Financing Cash Flow | 3.19M | 3.92M | 1.77M | 7.10M | 10.53M |
Zelira Therapeutics Technical Analysis
Neutral
0.34
Price Trends
0.57
Negative
0.47
Positive
0.43
Positive
Market Momentum
-0.01
Negative
38.51
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ZLD, the sentiment is Neutral. The current price of 0.34 is below the 20-day moving average (MA) of 0.50, below the 50-day MA of 0.57, and below the 200-day MA of 0.43, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 38.51 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:ZLD.
Zelira Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$34.90M | -2.50 | -258.19% | ― | 306.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$7.52M | -3.15 | -17.07% | ― | ― | 71.10% | |
48 Neutral | AU$13.12M | -1.00 | -218.76% | ― | ― | ― | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
42 Neutral | AU$24.94M | -5.38 | -19.10% | ― | ― | -672.73% | |
39 Underperform | AU$5.95M | -1.39 | 56.41% | ― | -99.31% | 90.20% |
* Healthcare Sector Average
AU:ZLD
Zelira Therapeutics
0.50
0.02
4.17%
AU:IXC
Invex Therapeutics Ltd.
0.10
0.03
38.89%
AU:CMB
Regeneus Ltd.
0.48
0.17
54.84%
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
AU:1AD
AdAlta Ltd.
―
―
―
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.08
0.03
87.50%
Zelira Therapeutics Corporate Events
Zelira Secures Director Loan on Premium-Priced Convertible Terms
Mar 10, 2026
Zelira Therapeutics has secured an unsecured AUD$50,000 working capital loan note from non-executive director Tim Slate on terms the board deems favourable given current market conditions. The funds will be applied to general working capital, supp...
Zelira Raises US$33m for HOPE® 1 SPV to Accelerate FDA Pathway
Jan 29, 2026
Zelira Therapeutics has secured definitive agreements for a transformative US$32.98 million capital raise into its HOPE® 1 special purpose vehicle (SPV), led by TGC Biotechnology Fund (ThirdGate Capital), valuing the SPV at roughly US$66 mill...
Zelira Secures US$33m Strategic Investment to Advance HOPE® 1 Autism Therapy
Jan 15, 2026
Zelira Therapeutics has secured binding agreements with TGC Biotechnology Fund (ThirdGate Capital) for a US$32.98 million equity investment into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million and Zelira’s po...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.